COLL
Collegium Pharmaceutical Inc
22.60$
+0.8%
vs. previous close
Closing price · As of: Sep 24, 2026
Statements
Income Statement
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 41.3% | 36.8% | 36.9% | 37.5% | 39.2% | 46.0% | 45.2% | 42.3% | 38.3% | 37.5% | 39.4% | 44.8% | 40.0% | |
| 58.7% | 63.2% | 63.1% | 62.5% | 60.8% | 54.0% | 54.8% | 57.7% | 61.7% | 62.5% | 60.6% | 55.2% | 60.0% | |
| 0.0% | 0.0% | – | – | – | – | – | – | – | – | – | – | – | |
| 25.8% | 17.1% | 29.0% | 29.8% | 38.9% | 26.4% | 43.0% | 39.2% | 32.1% | 32.9% | 44.6% | 53.3% | 40.5% | |
| 25.8% | 22.0% | 29.0% | 29.8% | 38.9% | 33.1% | 42.6% | 39.0% | 31.3% | 33.7% | 44.1% | 53.3% | 40.4% | |
| 32.9% | 41.2% | 34.1% | 32.7% | 21.9% | 20.9% | 12.2% | 18.7% | 30.4% | 28.8% | 16.5% | 1.9% | 19.6% | |
| 15.2% | 12.9% | 12.0% | 10.7% | 11.5% | 12.5% | 11.7% | 10.9% | 10.4% | 51.0% | 8.2% | 9.8% | 20.0% | |
| 21.1% | 31.2% | 25.3% | 20.0% | 9.8% | 9.5% | 1.8% | 9.1% | 20.7% | 14.1% | 9.7% | -6.8% | 9.6% | |
| 6.0% | 9.9% | 6.1% | 6.5% | 3.9% | 2.6% | 0.4% | 2.7% | 5.7% | 5.9% | 2.2% | 0.8% | 3.7% | |
| 15.1% | 21.3% | 19.1% | 13.5% | 5.9% | 6.9% | 1.4% | 6.4% | 15.0% | 8.3% | 7.5% | -7.5% | 5.9% | |
| 63.4% | 67.8% | 61.7% | 55.2% | 47.5% | 53.0% | 45.3% | 50.1% | 58.1% | 147.8% | 46.8% | 35.4% | 72.6% |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: September 24, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.